Compare WMK & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | AGIO |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2013 |
| Metric | WMK | AGIO |
|---|---|---|
| Price | $74.37 | $27.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 108.5K | ★ 920.2K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 6.99 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $4,894,832,000.00 | $44,791,000.00 |
| Revenue This Year | N/A | $27.83 |
| Revenue Next Year | N/A | $133.46 |
| P/E Ratio | $19.05 | ★ N/A |
| Revenue Growth | 2.20 | ★ 36.26 |
| 52 Week Low | $61.53 | $22.24 |
| 52 Week High | $90.23 | $46.00 |
| Indicator | WMK | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 75.74 | 48.36 |
| Support Level | $68.29 | $26.53 |
| Resistance Level | $69.31 | $29.93 |
| Average True Range (ATR) | 1.56 | 1.17 |
| MACD | 0.54 | 0.06 |
| Stochastic Oscillator | 94.37 | 43.34 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.